Article Information
History
- April 1, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Joshua J. Solomon, MD1,*,
- Sonye Danoff, MD2,*,
- Felix Woodhead, MD3,*,
- Shelley Hurwitz, PhD4,
- Rie Maurer, MS4,
- Ian Glaspole, MD5,
- Paul F. Dellaripa, MD4,
- Bibek Gooptu, MD6,
- Robert Vassallo, MD7,
- P. Gerald Cox, MD8,
- Kevin R. Flaherty, MD9,
- Huzaifa I. Adamali, MD10,
- Michael A. Gibbons, MD11,
- Lauren Troy, MD12,
- Ian Forrest, MD13,
- Joseph A. Lasky, MD14,
- Lisa G. Spencer, MD15,
- Jeffrey Golden, MD16,
- Mary Beth Scholand, MD17,
- Nazia Chaudhuri, MD18,
- Mark A. Perella, MD4,
- David Lynch, MD1,
- Daniel C. Chambers, MD19,
- Martin Kolb, MD8,
- Cathie Spino, PhD9,
- Ganesh Raghu, MD20,*,+,
- Hilary Goldberg, MD4,*,+,
- Ivan O. Rosas, MD21,*,+,†,
- the TRAIL1 Network Investigators**
- 1National Jewish Health, Denver, CO, USA
- 2Johns Hopkins, Baltimore, USA
- 3University of Leicester, UK
- 4Brigham and Women’s Hospital, Boston, USA
- 5Alfred Health, Melbourne, Australia
- 6Glenfield Hospital, Leicester, UK
- 7Mayo Clinic, Rochester, MN, USA
- 8McMaster University, Hamilton, ON, Canada
- 9Michigan University, Ann Arbor, MI, USA
- 10North Bristol NHS Trust, UK
- 11Royal Devon and Exeter Hospital, Exeter, UK
- 12Royal Prince Alfred Hospital, Camperdown, Australia
- 13Royal Victoria Infirmary, Newcastle upon Tyne, UK
- 14Tulane University, New Orleans, LA, USA
- 15University Hospital Aintree, Liverpool, UK
- 16University of San Francisco, San Francisco, CA, USA
- 17University of Utah, Salt Lake City, UT, USA
- 18Wythenshawe Hospital, Manchester, UK
- 19The Prince Charles Hospital, The University of Queensland, Australia
- 20University of Washington, Seattle, WA, USA
- 21Baylor College of Medicine, Houston, TX, USA
- ↵†Correspondence to: Ivan O. Rosas, MD. Baylor College of Medicine, Houston, TX, USA. ivan.rosas{at}bcm.edu
↵* Equal contribution
Posted April 01, 2022.
A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease
